Navigation Links
Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies
Date:11/9/2009

ion to the Shire ADHD portfolio. The availability of INTUNIV now allows physicians to prescribe the first and only nonscheduled alpha-2A receptor agonist indicated for the treatment of ADHD to help their patients manage a range of ADHD symptoms," said Michael Yasick, Senior Vice President of the ADHD Business Unit at Shire. "Shire is proud to provide physicians and the ADHD community with a novel treatment choice, which expands the range of available treatment options, allowing physicians to optimize the management of ADHD."

The commitment of Shire to making INTUNIV available for ADHD patients is consistent with the company's strategy to expand and diversify its ADHD portfolio, which now consists of four ADHD treatment options of scheduled and nonscheduled medicines in the United States and three medicines approved for the treatment of ADHD outside the United States.

About INTUNIV

The efficacy of INTUNIV in the treatment of ADHD was established in two, similarly designed, placebo-controlled clinical trials in children and adolescents aged 6 to 17 years who met Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for ADHD. Statistically significant improvements were reported by investigators, parents, and teachers.

The first pivotal trial was a phase III, double-blind, parallel-group trial, in which investigators randomized 345 children aged 6 to 17 years to either a placebo or a fixed 2-mg, 3-mg, or 4-mg dose of INTUNIV given once daily during an eight-week period. The second pivotal trial was a phase III, double-blind, parallel-group trial, in which investigators randomized 324 children aged 6 to 17 years to either a placebo or a fixed 1-mg, 2-mg, 3-mg, or 4-mg dose of INTUNIV given once daily during a nine-week period, with the 1 mg assigned only to patients weighing less than 50 kg (110 lbs).

In both trials, doses were increased in increments of 1 mg per week, and investigators eval
'/>"/>

Contact: Matt Cabrey
mcabrey@shire.com
484-595-8248
Porter Novelli
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine
2. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
3. Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study
4. New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
5. Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States
6. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
7. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
8. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
9. European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1
10. Once-Daily Combo Works for New HIV Patients
11. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... September 03, 2014 Independent review ... of appropriate evidence-based health care along the continuum. ... from the expertise of accredited independent review organizations ... care system. , As a core function, IROs ... settle questions of medical necessity. Yet backed by ...
(Date:9/2/2014)... Autumn is well under way ... the new season with worldwide people. Recently, it ... that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), Arvixe, and Bluehost ... , Since 2002 HostGator has been known ... company’s reputation for reliability remains with it today. ...
(Date:9/2/2014)... FL (PRWEB) September 03, 2014 Everyone of ... Beauty® offers two easy ways to help minimize them and ... care ingredients. Aging skin needs to boost collagen levels, which ... and sagging skin. Skin also needs to be well hydrated, ... protection from the sun and good diet that nourishes skin, ...
(Date:9/2/2014)... Chicago, IL (PRWEB) September 02, 2014 ... upcoming Ambulatory Surgery Center Educational Program on October ... Becker's ASC 21st Annual Meeting - The Business ... health system executives through high-quality continuing education, networking ... healthcare services and technologies. , Outstanding educational offerings ...
(Date:9/2/2014)... 2, 2014 4 pm EDT): In a Viewpoint published ... Association , a team of Boston researchers call for ... quality in the United States. The researchers from the ... University, Harvard University and Boston Children,s Hospital write that ... foods could both help people make meaningful dietary changes ...
Breaking Medicine News(10 mins):Health News:Independent Review Expands Its Scope: Case Studies in Context 2Health News:Independent Review Expands Its Scope: Case Studies in Context 3Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:2 Natural Ways to Relax and Reduce Wrinkles From Sublime Beauty® 2Health News:Becker's Healthcare Announces Ambulatory Surgery Center Educational Program 2Health News:Becker's Healthcare Announces Ambulatory Surgery Center Educational Program 3Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2
... skin cancer in men has increased by 12% in six years, ... year are now diagnosed with the disease, 3,000 of those are ... in men is that they tend to occur more commonly on ... leg and more noticeable. Up to 77% of cases are caused ...
... Research suggests that anxiety during pregnancy can increase a ... indicated that women who were very anxious// in the ... behavioural problems. ,Lead researcher Professor Vivette Glover, ... to women who had extreme anxiety, and were frequently ...
... way to predict when somebody is likely to have ... occur suddenly and without warning and can lead to ... de la Pitie-Salpetriere, Paris, believe ,it may be possible ... an electroencephalogram ,(EEG). ,An ECG records electrical activity ...
... for more than 100 years. And while most of the ... the use of aspirin has increased. This powerful pill will ... the risk of heart attacks and stroke. ,In ... were first discovered, relatively few drugs have been developed that ...
... have the option of having one blast of radiotherapy ... 25 sessions afterwards, researchers said. //They believe the new ... and may improve the treatment of breast cancer for ... world. ,Dr. Emiel Rutgers, of the Netherlands Cancer ...
... developed for preventing and treating the flue have shown ... dose to be effective.// The compounds, known collectively as ... relenza, or zanamivir, which the U.S. Food and Drug ... B. ,Researchers reported at the International Conference on ...
Cached Medicine News:
(Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com ... available in its catalogue: Acute Heart ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute ... Summary GlobalData,s clinical trial report, ... 2014" provides data on the Acute Heart Failure ...
(Date:9/2/2014)... 2014    - Los ... agentes antitrombóticos no utilizados óptimamente para prevenir la ... presentaciones de GARFIELD-AF en el ESC CONGRESS 2014 ... resultados de pacientes en riesgo de sufrir apoplejía ... Los datos de casi 12.500 pacientes reclutados ...
(Date:9/2/2014)... , -- GARFIELD-AF ... into treatment and outcomes of patients at risk ... Data from nearly 12,500 patients enrolled ... Fibrillation (GARFIELD-AF), an innovative, independent academic research initiative, ... fibrillation (AF) patients remain sub-optimal despite the transition ...
Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... HORSHAM, Pa. , July 28 Teva Respiratory ... efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol ... all efficacy endpoints, demonstrating a statistically significant benefit as compared to ... similar to placebo. , , ...
... BOCA RATON, Fla. , July 28 ... Pharma, the company will market Methylphenidate Solution, the generic ... an Abbreviated New Drug Application (ANDA).  Under the terms ... Tris Pharma, and marketed and distributed by Breckenridge on ...
Cached Medicine Technology:Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 2Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 3Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 4Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 5Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 6Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ) 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: